Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia

The Lancet Oncology

Volumn 10, Issue 2, 2009, Pages 147-156

  Coustan Smith, Elaine ^a   Mullighan, Charles G ^a   Onciu, Mihaela ^a   Behm, Frederick G ^a   Raimondi, Susana C ^a,b   Pei, Deqing ^a   Cheng, Cheng ^a   Su, Xiaoping ^a   Rubnitz, Jeffrey E ^a,b   Basso, Giuseppe ^c   Biondi, Andrea ^d   Pui, Ching Hon ^a,b   Downing, James R ^a,b   Campana, Dario ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD5 ANTIGEN; CD8 ANTIGEN; T6 ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; EARLY CANCER; EARLY DIAGNOSIS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENOMIC INSTABILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INFANT; ITALY; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LYMPHOBLAST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; T CELL LEUKEMIA; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOPHENOTYPING; INFANT; KAPLAN-MEIERS ESTIMATE; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTORS;

EID: 58749095816     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70314-0     Document Type: Article

References (40)

1. Goldberg J.M., Silverman L.B., Levy D.E., et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 21 (2003) 3616-3622
2. Pui C.H., and Evans W.E. Treatment of acute lymphoblastic leukemia. N Engl J Med 354 (2006) 166-178
3. Pullen J., Shuster J.J., Link M., et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study. Leukemia 13 (1999) 1696-1707
4. Thiel E., Kranz B.R., Raghavachar A., et al. Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood 73 (1989) 1247-1258
5. Pui C.H., Hancock M.L., Head D.R., et al. Clinical significance of CD34 expression in childhood acute lymphoblastic leukemia. Blood 82 (1993) 889-894
6. Pui C.H., Rivera G.K., Hancock M.L., et al. Clinical significance of CD10 expression in childhood acute lymphoblastic leukemia. Leukemia 7 (1993) 35-40
7. Ferrando A.A., Neuberg D.S., Staunton J., et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1 (2002) 75-87
8. Ferrando A.A., Neuberg D.S., Dodge R.K., et al. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet 363 (2004) 535-536
9. Cave H., Suciu S., Preudhomme C., et al. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. Blood 103 (2004) 442-450
10. Breit S., Stanulla M., Flohr T., et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 108 (2006) 1151-1157
11. Rothenberg E.V., Moore J.E., and Yui M.A. Launching the T-cell-lineage developmental programme. Nat Rev Immunol 8 (2008) 9-21
12. Bell J.J., and Bhandoola A. The earliest thymic progenitors for T cells possess myeloid lineage potential. Nature 452 (2008) 764-767
13. Wada H., Masuda K., Satoh R., et al. Adult T-cell progenitors retain myeloid potential. Nature 452 (2008) 768-772
14. Balciunaite G., Ceredig R., and Rolink A.G. The earliest subpopulation of mouse thymocytes contains potent T, significant macrophage, and natural killer cell but no B-lymphocyte potential. Blood 105 (2005) 1930-1936
15. Weerkamp F., Baert M.R., Brugman M.H., et al. Human thymus contains multipotent progenitors with T/B lymphoid, myeloid, and erythroid lineage potential. Blood 107 (2006) 3131-3137
16. Tydell C.C., David-Fung E.S., Moore J.E., Rowen L., Taghon T., and Rothenberg E.V. Molecular dissection of prethymic progenitor entry into the T lymphocyte developmental pathway. J Immunol 179 (2007) 421-438
17. Pui C.H., Sandlund J.T., Pei D., et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 104 (2004) 2690-2696
18. Pui C.H., Pei D., Sandlund J.T., et al. Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 23 (2005) 7936-7941
19. Conter V., Schrauder A., Gadner H., et al. Impact of minimal residual disease on prognosis in children with acute lymphoblastic leukemia according to white blood cell count, age and TEL/AML1 status at diagnosis. results of the AIEOP-BFM ALL 2000 study. Blood 110 (2007) abstr 167a.
20. Mullighan C.G., Goorha S., Radtke I., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446 (2007) 758-764
21. Database of genomic variants. http://projects.tcag.ca/variation (accessed Dec 17, 2008).
22. Subramanian A., Tamayo P., Mootha V.K., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102 (2005) 15545-15550
23. Coustan-Smith E., Behm F.G., Sanchez J., et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 351 (1998) 550-554
24. Coustan-Smith E., Sancho J., Hancock M.L., et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96 (2000) 2691-2696
25. van Dongen J.J., Seriu T., Panzer-Grumayer E.R., et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352 (1998) 1731-1738
26. Smyth G.K. Limma: linear models for microarray data. In: Gentleman R., Carey V., Dudoit S., Irizarry R., and Huber W. (Eds). Bioinformatics and computational biology solutions using R and bioconductor (2005), Springer, New York 397-420
27. Tibshirani R., Hastie T., Narasimhan B., and Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 99 (2002) 6567-6572
28. Kalbfleisch J.D., and Prentice R.L. The statistical analysis of failure time data (1980), John Wiley & Sons, New York (NY)
29. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988) 1141-1154
30. Fine J.P., and Gray J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999) 496-509
31. Baldus C.D., Burmeister T., Martus P., et al. High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol 24 (2006) 4714-4720
32. Radtke F., Wilson A., Mancini S.J., and MacDonald H.R. Notch regulation of lymphocyte development and function. Nat Immunol 5 (2004) 247-253
33. Maser R.S., Choudhury B., Campbell P.J., et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447 (2007) 966-971
34. Arico M., Basso G., Mandelli F., et al. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Cancer 75 (1995) 1684-1693
35. Paietta E., Ferrando A.A., Neuberg D., et al. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood 104 (2004) 558-560
36. Campana D., and Behm F.G. Immunophenotyping of leukemia. J Immunol Methods 243 (2000) 59-75
37. Bene M.C., Bernier M., Casasnovas R.O., et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood 92 (1998) 596-599
38. Shuster J.J., Falletta J.M., Pullen D.J., et al. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 75 (1990) 166-173
39. Uckun F.M., Gaynon P.S., Sensel M.G., et al. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. J Clin Oncol 15 (1997) 2214-2221
40. Schrauder A., Reiter A., Gadner H., et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol 24 (2006) 5742-5749